

AGENDA

Mayflower Renaissance Hotel, 1127 Connecticut Avenue NW

Wednesday, February 25th

4:00-8:00 pm *Registration open.....Grand Ballroom Promenade*

6:30-8:30 pm **Welcome Reception: "Fighting melanoma on all fronts"****East/State Room**

Thursday, February 26th

6:30 am-6:00 pm *Registration open.....Grand Ballroom Promenade*

7:00-8:15 am General Breakfast.....East/State Room

7:00-8:15 am Young Investigators Breakfast (by invitation only).....Chinese Room
"So you want to develop a treatment for melanoma?
Stories from the front lines"

8:30-8:45 am **Opening Remarks**.....**Grand Ballroom**
Wendy Selig, MRA President & Chief Executive Officer
Louise Perkins, MRA Chief Science Officer

8:45-9:10 am **Lecture: Improving survival for patients with melanoma: all hands on deck:**
Lynn Schuchter, University of Pennsylvania

9:10-10:45 am **Session: Discovery and integration of novel targets into melanoma therapy**
Chair: Marcus Bosenberg

9:10-9:35 Targeting CDK4/6 in melanoma: Andrew Aplin, Thomas Jefferson University

9:35-9:55 Blockade of a novel CTLA-4 pathway as a new approach in melanoma therapy:
Kok-Fai Kong, La Jolla Institute for Allergy and Immunology

9:55-10:20 Downregulation of the ubiquitin ligase RNF125 underlies resistance of melanoma cells to BRAF inhibitors via JAK1 and EGFR deregulation: Ze'ev Ronai, Sanford-Burnham Medical Research Institute

10:20-10:45 Modeling the role of epigenetics in melanoma: Marcus Bosenberg, Yale University

10:45-11:05 am *BREAK*

11:05 am-12:25 pm **Session: Melanoma biology, prevention, and early detection**
Chair: Glenn Merlino

11:05-11:10 Recap of recent policy achievements: Wendy Selig, MRA

Thursday, February 26th (cont.)

- 11:10-11:35 Modeling initiation, progression and treatment of human melanoma in the mouse: Glenn Merlino, U.S. National Cancer Institute
- 11:35-12:00 Interaction of UVR and melanoma driver genes: Richard Marais, Cancer Research UK Manchester Institute
- 12:00-12:25 Melanoma prevention and diagnosis: an update: Allan Halpern, Memorial Sloan Kettering Cancer Center
- 12:30-1:30 pm Lunch and Speaker.....East/State Room**
Francis Collins, Director, National Institutes of Health
- 1:45-2:10 pm Lecture: Adjuvant therapy of melanoma: challenges and potential inroads.....Grand Ballroom**
John Kirkwood, University of Pittsburgh
- 2:10-4:05 pm Session: Accelerating early biomarkers of resistance and treatment response**
Chair: Marisol Soengas
- 2:10-2:35 Single cell technologies for understanding immune-cell tumor cell interactions: James Heath, California Institute of Technology
- 2:35-3:00 Cancer genomes and immunotherapy efficacy: Timothy Chan, Memorial Sloan Kettering Cancer Center
- 3:00-3:20 pm *BREAK*
- 3:20-3:40 New modalities for measuring response to immune checkpoint blockade: Evan Lipson, Johns Hopkins University
- 3:40-4:05 Imaging and therapeutic targeting of lymphangiogenesis in melanoma metastasis: Marisol Soengas, Spanish National Cancer Research Center
- 4:05-4:30pm Lecture: The future of translational melanoma research: a provocative overview: Antoni Ribas, University of California, Los Angeles**
- 4:30-4:45 pm Closing Remarks: Wendy Selig**
- 6:30-10:00 pm Reception and Dinner..... Teddy & The Bully Bar**
Dress: Casual
1200 19th St. NW, (202) 872-8700
6:30-7:30 Reception; 7:30 Dinner

Friday, February 27th

- 6:30-10:00 am Registration open.....Grand Ballroom Promenade
- 7:00-8:30 am General Breakfast.....East/State Room
- 7:00-8:30 am Industry Roundtable Breakfast (by invitation only).....Colonial Room
“Post-approval optimization of new melanoma drugs”
- 8:50-9:00 am Opening Remarks:** Louise Perkins, MRA Chief Science Officer.....**Grand Ballroom**
- 9:00-9:25 am Lecture: Addressing difficult to treat metastatic disease:** Caroline Robert,
Institute Gustave Roussy
- 9:25-11:15 am Session: Advancing combination therapy approaches**
Chair: Jeffrey Weber
- 9:25-9:45 PI3K and BRAF inhibitor combination therapy: Tara Gangadhar, University of
Pennsylvania
- 9:45-10:10 Understanding responses to therapy and rationale for combination strategies:
Jennifer Wargo, MD Anderson Cancer Center
- 10:10-10:30 *BREAK*
- 10:30-10:50 Augmenting adoptive T cell therapy with IL-2 and IL-15: Mark Rubinstein,
Medical University of South Carolina
- 10:50-11:15 Pre-clinical and clinical assessment of checkpoint protein inhibition with adoptive
cell therapy using tumor infiltrating lymphocytes: Jeffrey Weber, Moffitt Cancer
Center
- 11:15-11:40 am Lecture: The future of immune checkpoint blockade:** James Allison,
MD Anderson Cancer Center
- 11:40 am-11:45 pm Closing Remarks:** Jeffrey Rowbottom, MRA Board Member
- 12:00-1:00 pm General Lunch.....East/State Room